Approvals/TGA/ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial

Approved

STANDARD

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial

Approval Id: 5e83c92172d1e12c
Product Name: ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial
Artg Id: 330566
Artg Name: ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial
Sponsor: Alexion Pharmaceuticals Australasia Pty Ltd
Company Detail Path: /organization/alexion-pharmaceuticals-australasia-pty-ltd
Artg Date: 2021-03-23
Registration Type: Medicine
Therapeutic Good Type: Medicine
Licence Status: A
Licence Category: RE
Consumer Medicine Info: https://medical-cdn.nocode.com/drug_tga/03673dee6a630d3b5fe10624f5268b1e.pdf
Product Information: https://medical-cdn.nocode.com/drug_tga/9f7ff1e1863095aa340de0da9ff657ec.pdf

Approved

Agency

TGA

Country

🇦🇺

Approval Date

Dec 9, 2025

Approval ID

5e83c92172d1e12c

Type

Standard